

Remdesivir - COVID-19 - India

(Repurposing Scan)

Report ID: REP-20251216-f618f4
Generated At: 2025-12-16T12:41:17.409491
Format: pdf

Executive Summary

- Remdesivir is included in authoritative COVID-19 treatment guidelines from major organizations such as WHO and NICE, though no specific Indian national guideline was found. Recent publications cover its clinical use, safety signals like bradycardia, and sequence treatment in complex cases. News from India highlights regulatory approvals, guidelines issued by local health authorities, black marketing issues, export restrictions, and supply challenges for remdesivir during the COVID-19 pandemic. Overall, evidence and real-world use support remdesivir as part of COVID-19 management in India, with ongoing safety and effectiveness monitoring.

Clinical Trials

Summary

- Active trials: 4
- Completed trials: 1
- Phase distribution: Phase Observational (1) Phase Phase 1 (0) Phase Phase 2 (3) Phase Phase 3 (0) Phase Phase 4 (1)

Highlights

- No Phase III trials identified in India

Top Trials

Trial ID	Title	Phase	Status	Locations	Start Date
NCT04854837	Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis	Observational	Completed	Hungary	2021-04-12
NCT04386447	Phase II, Multicenter, Open-	Phase 2	Active	Italy, France	2020-09-01

Trial ID	Title	Phase	Status	Locations	Start Date
	label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19				
NCT04403477	Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT	Phase 2	Active	Bangladesh	2020-05-20
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Phase 2	Active	Canada	2020-04-17
NCT06792214	Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/ Remdesivir Effectiveness For the prEvention of loNg covid (DEFEND) Clinical Trial	Phase 4	Active	Canada	2025-01-03

Guidelines and Literature

Guidelines

- **WHO Guidelines:** Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).

- **NICE Guidelines:** Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

Publications

- **PMID 40255942 (2024):**
- **PMID 40161930 (2025):**
- **PMID 40057834 (2024):**
- **PMID 39816292 (2024):**
- **PMID 39811032 (2024):**
- **PMID 39772165 (2024):**
- **PMID 39756947 (2024):**
- **PMID 39743047 (2025):**
- **PMID 39739156 (2025):**
- **PMID 39737903 (2024):**

Repurposing Options

- **Targeted subgroup usage**

Rationale: Remdesivir is included in authoritative COVID-19 treatment guidelines from major organizations such as WHO and NICE, though no specific Indian national guideline was found. Recent publications cover its clinical use, safety signals like bradycardia, and sequence treatment in complex cases. News from India highlights regulatory approvals, guidelines issued by local health authorities, black marketing issues, export restrictions, and supply challenges for remdesivir during the COVID-19 pandemic. Overall, evidence and real-world use support remdesivir as part of COVID-19 management in India, with ongoing safety and effectiveness monitoring.

Evidence: WHO Guidelines, NICE Guidelines

Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

References

- **Guideline:** WHO Guidelines — <https://www.who.int/publications/guidelines>
- **Guideline:** NICE Guidelines — <https://www.nice.org.uk/guidance>
- **Publication:** PMID:40255942 — <https://pubmed.ncbi.nlm.nih.gov/40255942/>
- **Publication:** PMID:40161930 — <https://pubmed.ncbi.nlm.nih.gov/40161930/>
- **Publication:** PMID:40057834 — <https://pubmed.ncbi.nlm.nih.gov/40057834/>
- **Publication:** PMID:39816292 — <https://pubmed.ncbi.nlm.nih.gov/39816292/>
- **Publication:** PMID:39811032 — <https://pubmed.ncbi.nlm.nih.gov/39811032/>
- **Publication:** PMID:39772165 — <https://pubmed.ncbi.nlm.nih.gov/39772165/>
- **Publication:** PMID:39756947 — <https://pubmed.ncbi.nlm.nih.gov/39756947/>

- **Publication:** PMID:39743047 — <https://pubmed.ncbi.nlm.nih.gov/39743047/>
- **Publication:** PMID:39739156 — <https://pubmed.ncbi.nlm.nih.gov/39739156/>
- **Publication:** PMID:39737903 — <https://pubmed.ncbi.nlm.nih.gov/39737903/>
- **Trial:** NCT04854837 — <https://clinicaltrials.gov/study/NCT04854837>
- **Trial:** NCT04386447 — <https://clinicaltrials.gov/study/NCT04386447>
- **Trial:** NCT04403477 — <https://clinicaltrials.gov/study/NCT04403477>
- **Trial:** NCT04321993 — <https://clinicaltrials.gov/study/NCT04321993>
- **Trial:** NCT06792214 — <https://clinicaltrials.gov/study/NCT06792214>

Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**